Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Verona Pharma Limited has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units, indicating that each pending matter is associated with a separate examiner and technical examination assignment.
HAGHIGHATIAN, MINA is the busiest examiner, with 1 pending matter. The distribution provides no indication that one examiner or art unit dominates the portfolio. Practitioners should manage the matters independently and avoid assuming that prosecution developments in one assignment will directly carry over to the other.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGHIGHATIAN, MINA | 1 | 45.9% | +39.5% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.2% | -6.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18616878 | PHARMACEUTICAL COMPOSITIONS COMPRISING RPL554 IN HFA-134A FOR ADMINISTRATION BY INHALATION | HAGHIGHATIAN, MINA | 5d overdue |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18616878 | PHARMACEUTICAL COMPOSITIONS COMPRISING RPL554 IN HFA-134A FOR ADMINISTRATION BY INHALATION | HAGHIGHATIAN, MINA | 1616 | §103Other | Final Rejection | 5d overdue | Pending | Mar 26, 2024 |
| 18417410 | LIQUID PHARMACEUTICAL COMPOSITION | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Final Rejection | 34d | Pending | Jan 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVerona Pharma Limited has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Mina Haghighatian has the most, with 1 of Verona Pharma Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.